• Bryce J Bonin, Scott Beckman, Sultan Mahmud, Danielle Terrell, Stephen Garrett Whipple, Ryan Diaz, Nobel BhuiyanMohammad AlfradMADepartment of Internal Medicine at Louisiana State University Health Science Center, Shreveport, Louisiana, USA., Deepak Kumbhare, Chiachien Jake Wang, Bharat Guthikonda, and Amey R Savardekar.
• Department of Neurosurgery at Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
• World Neurosurg. 2024 Nov 14; 194: 123304123304.

ObjectiveTo analyze the literature regarding the use of stereotactic radiosurgery as the primary treatment of vestibular schwannoma to further evaluate efficacy and treatment-related neurologic deficits.MethodsOnline databases were queried to identify relevant studies from January 2001 to December 2020. Full-text articles in English for sporadic vestibular schwannoma treated primarily with radiosurgery and documented hearing preservation data were reviewed. Studies that had a minimum follow-up period of less than 36 months, did not use radiosurgery for primary treatment, or included patients with neurofibromatosis type 2 were excluded.ResultsA total of 33 studies involving 4286 patients with an average follow-up of 62.5 months were included in the final analysis. All 33 studies included eligible hearing data; overall preservation of serviceable hearing was found to be 58.27%. Twenty-seven studies with 3822 eligible patients were analyzed for tumor control rates; overall, tumor control was reported in 92.98% of cases. Twenty-seven studies were analyzed for posttreatment facial nerve dysfunction, which was reported in 1.53% of cases.ConclusionsStereotactic radiosurgery is a safe and effective primary treatment modality for sporadic vestibular schwannoma as shown by the present analysis. Radiosurgery is effective regarding tumor control and hearing preservation and offers a low rate of posttreatment facial nerve dysfunction.Copyright © 2024 Elsevier Inc. All rights reserved.

6 keywords...

hide…